Results 211 to 220 of about 6,850,919 (315)

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

The Management of Withdrawal From Alcohol and Other Drugs in Australian Custodial Settings: A Consensus Statement. [PDF]

Med J Aust
FitzGerald G, Chan J, Cook J, Stoove M, Curtis M, Nielsen S, Winter RJ, Naren T.   +7 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Drug Safety Assessment Based on Target Affinity, Drug Exposure and Plasma Protein Binding: Drug-Induced Cardiotoxicity from a Translational Pharmacology Perspective. [PDF]

Int J Mol Sci
Catozzi S, Sips F, Totis N, Bisotti MA, Stathopoulos S, Torchia M, Emili L, Carbone V, Baker C, Mahoney JM, Röshammar D, Cardioverse Project Team.   +11 more
europepmc   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Supply Chain Events and Risk of Drug Shortage in Canada.

JAMA Netw Open
Santhireswaran A, Ho MKH, Kim KC, Chaudhry S, Suda KJ, Gaudette E, Burry L, Tadrous M.   +7 more
europepmc   +1 more source

Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance. [PDF]

J Pharm Pharm Sci
Srikanth G, Praveen Kumar N, Sridevi B, Borra PB, Thapar P, Wani A.   +5 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

A multi-modal co-attention model for accurate drug-target interaction prediction. [PDF]

PLoS One
Ma W, Li W, Yang M, Pu Z, Tang X.
europepmc   +1 more source